Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Eligibility Criteria

• * Voluntary written informed consent to participate in the study
• * Active subfoveal MNV (any subtype) or juxtafoveal MNV secondary to AMD with leakage affecting the fovea in the study eye at screening
• * BCVA ETDRS letter score of 78 letters to 35 letters in the study eye as measured by the ETDRS visual acuity chart at screening
• * CST ≥ 450 μm at screening
• * Subretinal hemorrhage, fibrosis, or atrophy of \> 50% of the total lesion area and/or that involves the fovea in the study eye
• * Uncontrolled glaucoma in the study eye
• * Aphakia or pseudophakia with AC-IOL in the study eye
• * Active intraocular inflammation in the study eye
• * Any current ocular condition for which visual acuity loss would not improve from resolution of macular edema in the study eye
• * History of rhegmatogenous retinal detachment in the study eye
• * Any current or history of ocular disease other than nAMD in the study eye that may confound assessment of the macula or affect central vision
• * History of the following therapies in the study eye:
• * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
• * Prior treatment PDT with Visudyne®, external-beam radiation therapy, transpupillary thermotherapy, or panretinal photocoagulation
• * Previous use of periocular or intraocular (sub-Tenon or IVT) corticosteroids
• * Previous intraocular device implantation except PC-IOL
• * Previous laser (any type) to the macular area
• * Previous treatment with IVT anti-VEGF drugs other than ranibizumab, bevacizumab, aflibercept 2 mg, and their biosimilars;
• * Previous treatment with ranibizumab, bevacizumab, aflibercept 2 mg, or their biosimilars within 12 weeks before being enrolled to the study. If a previously treated patient is enrolled, the patient should be diagnosed with AMD within 3 years before being enrolled to the study.
• * Any current or history of endophthalmitis in either eye
• * History of idiopathic or autoimmune-associated uveitis in either eye
• * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye